HPV-SLP: Phase II started

ISA began an open-label, U.S. Phase II trial to evaluate 100 ug subcutaneous ISA101 every 3-4 weeks for up to 3 doses plus Opdivo nivolumab every 2 weeks starting on day 8 after vaccination with ISA1...